SSelectStock
Sign in

AJANTPHARMAjanta Pharma Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-19 (delayed ~30 min in market hours)

3,419.40
0.97%
81Excellent

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)43,155.30
P/E40.86
P/B9.53
PEG2.20
ROE %25.39
ROCE %27.70
Debt / Equity0.06
EPS84.54
Revenue Growth %21.50
Profit Growth %18.60
Dividend Yield %0.81
Promoter Holding %54.48
FII Holding %21.68
DII Holding %
Beta0.18

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG80%3,419.403,290.903,635.401.68
BUYConfidence 92%
  • Revenue growth: 21.5% YoY
  • Profit growth: 18.6% YoY
  • ROE: 25.4%
  • RSI: 63
  • MACD: bullish
  • Price vs EMA21: above
  • Pullback to 21-EMA signal (confidence 80%)

Bull case

  • Revenue growth: 21.5% YoY
  • Profit growth: 18.6% YoY
  • ROE: 25.4%
  • RSI: 63

Bear case

  • Volume: 0.7x 20-day average
  • Volume trend: 0.7x baseline

Key risks

  • Volume: 0.7x 20-day average
  • Volume trend: 0.7x baseline

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹3,419.40
Stop Loss
₹3,159.16
risk 7.6%
Target 1 (1.5R)
₹3,809.76
+11.4%
Target 2 (3R)
₹4,200.11
+22.8%
Support (20d)
₹3,071.20
Resistance (52w)
₹3,506.90
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹260.24/share
ATR (volatility)
₹104.10
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹104.10). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
81
Technical
78
Momentum
87
Risk (safety)
78

Peers — Pharma

PGHL 0.80%
83
GRANULES 2.49%
81
HESTERBIO 0.42%
80
CORONA 0.13%
80
SUNPHARMA 0.90%
79
LUPIN 1.58%
78

About

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.